Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
Filter by
-
GSK announces headline phase III results of mepolizumab in patients with severe chronic obstructive pulmonary disease
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced preliminary results of two pivotal phase III s...
Read more -
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Primary endpoint showed patients initiated with Relvar Ellipta had twice the odds of achieving an...
Read more -
GSK delivers another quarter of continued progress
GSK delivers another quarter of continued progress Q1 sales of £7.4 billion, +19% AER, + 5% CER ...
Read more -
GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Follows regulatory submissions in US, EU and Canada
Read more -
Togo becomes first country in Africa to validate the elimination of lymphatic filariasis as a public health problem
LF, commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted t...
Read more -
GSK makes change to financial reporting framework
GSK keeps its financial reporting framework under regular review to ensure that it remains curren...
Read more -
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
Read more -
GSK announces new scholarships to recognise retiring CEO Sir Andrew Witty’s contribution to global health
GSK today announced a new partnership with the London School of Hygiene & Tropical Medicine to es...
Read more -
UK Biobank, GSK and Regeneron announce largest gene sequencing initiative on world’s most detailed health database to improve drug discovery and disease diagnosis
Groundbreaking UK/US initiative will deliver first data within a year
Read more -
GSK’s MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
MUSCA study shows asthma patients achieved improvements in their health-related quality of life a...
Read more -
GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen
GSK today announced the closure of an agreement with Aspen aligned with GSK’s strategy of simplif...
Read more -
Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma
Positive headline results from a non-inferiority lung function study
Read more -
ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment
Headline results were announced in December 2016 and detailed study results are being presented a...
Read more -
Results announcement for the fourth quarter 2016
View full Q4 2016 Results (PDF)
Read more -
Abbas Hussain to leave GSK
Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company.
Read more -
Luke Miels appointed President, Global Pharmaceuticals, GSK
Luke Miels has been appointed President, Global Pharmaceuticals, GSK.
Read more -
GSK confirms closure of agreement to divest non-core assets to Aspen
GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmac...
Read more -
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention
First injectable to be studied for efficacy in pre-exposure prophylaxis
Read more -
GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma
The start of a phase III study investigating the effects of once-daily closed triple combination ...
Read more -
GSK announces Board changes
the creation of a new Board committee and a number of changes to the membership of the Board and ...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
